Most Clicked BIO SmartBrief Stories


1. Drug firms, NHS, academia team up for genome project

BIO SmartBrief | Mar 27, 2015

Ten drug companies, including AstraZeneca, GlaxoSmithKline and Roche, agreed to work with NHS Genomic Medicine Centres and academia to map 100,000 genomes of patients who have cancers and rare diseases. The drug firms will provide financing and researchers for the project, which has a targeted completion date of 2017. PharmaTimes (U.K.) (03/26)


2. Sun Pharmaceutical wraps up merger with Ranbaxy

BIO SmartBrief | Mar 26, 2015

The merger of Sun Pharmaceutical with Ranbaxy has been completed in a $4 billion deal, creating a combined company that will operate in 65 countries. The merger makes Sun one of the largest specialty generic drugmakers globally. PharmaTimes (U.K.) (03/25)


3. European Commission OKs Novo Nordisk's liraglutide injection for obesity

BIO SmartBrief | Mar 25, 2015

Novo Nordisk has won the European Commission's approval to market an injectable formulation of its diabetes drug liraglutide as a treatment for obesity. The drug, which will be offered as Saxenda in the 28 European Union member countries, is indicated for overweight or obese adults with one or more health conditions related to weight, such as type 2 diabetes, hypertension and obstructive sleep apnea. Tech Times (03/24)


4. Shire, Ohio children's hospital to collaborate on rare disease treatments

BIO SmartBrief | Mar 30, 2015

Shire has entered into a three-year research and development alliance with Cincinnati Children's Hospital Medical Center to develop new treatments for rare diseases. The agreement boosts Shire's Phase I rare disease product portfolio. PMLive.com (U.K.) (03/27)


5. GlaxoSmithKline, U.K. enter meningitis B vaccine deal

BIO SmartBrief | Mar 30, 2015

GlaxoSmithKline has reached an agreement with the U.K. government for its Bexsero meningitis B vaccine to be included in the country's national childhood immunization program. Children will be given a dose of the vaccine starting at the age of 2 months, with two other shots to follow. PharmaTimes (U.K.) (03/29)


6. Teva announces $3.5B purchase of Auspex Pharmaceuticals

BIO SmartBrief | Mar 31, 2015

Auspex Pharmaceuticals will be acquired by Teva Pharmaceutical in a deal worth $3.5 billion, or $101 per share. The purchase, which is expected to be close in the middle of this year, will strengthen Teva's pipeline of central nervous system treatments. Teva expects sales of Auspex products to reach $2 billion in 2020. Reuters (03/30)


7. HHS funds late-stage trial of Emergent's improved anthrax vaccine

BIO SmartBrief | Mar 25, 2015

HHS signed a $31 million deal with Emergent Biosolutions to fund the late-stage trials of Emergent's NuThrax, an anthrax vaccine that requires just two doses to provide immunity. NuThrax is an improved version of the BioThrax anthrax vaccine, which has been used for over a decade. Reuters (03/23)


8. Treeway receives orphan drug designation for ALS treatment

BIO SmartBrief | Mar 25, 2015

The FDA has designated Treeway's experimental treatment TW001 an orphan drug for patients with amyotrophic lateral sclerosis. There is no cure for the disease, and the only approved treatment confers only a modest survival benefit. PMLive.com (U.K.) (03/24)


9. Horizon Pharma to buy Hyperion Therapeutics

BIO SmartBrief | Mar 31, 2015

Horizon Pharma acquired Hyperion Therapeutics in a deal worth $1.1 billion. At the center of the deal is Hyperion's two orphan drugs, Ravicti and Buphenyl, for the treatment of urea cycle disorders. The purchase will diversify Horizon's portfolio of orphan disease treatments, the company said. American City Business Journals (03/30)


10. AstraZeneca, Harvard sign stem cell partnership to develop diabetes therapy

BIO SmartBrief | Mar 27, 2015

AstraZeneca and the Harvard Stem Cell Institute have agreed to a five-year research alliance to develop novel diabetes treatments using human beta cells. The work will be based on a method developed by the institute to produce beta cells from human induced pluripotent stem cells. Genetic Engineering & Biotechnology News (03/25)




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more